ZOM stock will rise if the company does two things: It needs to impress veterinary clinics of the utility of its Truforma platform, and build out its direct sales team to do so. ZOM Stock and Youthful Trouble Zomedica is an animal health company which only recently began selling its point-of-care veterinary diagnostics platform, Truforma.
Full Answer
Should you buy zomedica (Zom) stock at its low price?
At its current low price, ZOM stock may also attract bargain hunters. Wall Street seems bullish on Zomedica as well, with analysts' average price target of $1.20 implying a 60 percent upside over its current price. Bears are also unwinding their short bets on ZOM, and short interest has dropped to less than 6 percent.
Where is zomedica based?
Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. IDXX: IDEXX Laboratories vs. Zomedica: Which Pet Stock is a Better Investment for 2022?
Will zomedica’s truforma diagnostic platform drive Zom stock higher?
Adding to the heat, Zomedica recently announced the first commercial sale of its new product, the Truforma diagnostic platform. In anticipation of that product’s release, ZOM stock has risen to as high as $2.91 in February. Right now, it’s up 467% year-to-date (YTD).
What price target do analysts set for zomedica?
What price target have analysts set for ZOM? 1 equities research analysts have issued 12-month price targets for Zomedica's shares. Their forecasts range from $0.30 to $0.30. On average, they anticipate Zomedica's share price to reach $0.30 in the next year.
Is Zomedica stock a good buy?
In the final analysis, ZOM stock is highly risky and best suited for speculative traders. Yet it's possible that retail traders will bid the stock up in 2022. And if they abandon Zomedica, it would be a dog-gone shame.
Does Zomedica have a future?
Zomedica Corp (NYSE American:ZOM) The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +364.40% increase from the last price of 0.26.
Will Zomedica rise?
Zomedica Stock Price Forecast 2022-2023 The forecasted Zomedica price at the end of 2022 is $0.32 - and the year to year change +4%. The rise from today to year-end: +36%. In the middle of 2022, we expect to see $0.30 per 1 Zomedica.
What is wrong with Zomedica stock?
Key Points. Zomedica's shares have plunged more than 80% after skyrocketing earlier this year. The company has experienced problems with a distribution partner being acquired and a development partner's delays. Zomedica could rebound once new assays for its Truforma instrument are available.
Will Zomedica stock go up tomorrow?
Tomorrow's movement Prediction of Zomedica Pharmaceuticals Corp ZOM as on 14 Jul 2022 appears strongly Bullish. This stock started moving upwards as soon as it opened....Munafa value: 65 as on 14 Thu Jul 2022.Upside target0.28Downside target0.243 more rows
Is Zomedica being shorted?
Zomedica Short Interest - Frequently Asked Questions Short interest is the volume of Zomedica shares that have been sold short but have not yet been covered or closed out. As of June 30th, traders have sold 89,340,000 shares of ZOM short. 9.26% of Zomedica's shares are currently sold short.
Will ZOM stock go up in 2021?
Will Zom Stock Go Up? Zomedica's share price has been in a slump for the major part of 2021. Get more Shares news. The new year has not brought any significant changes in fortune.
Why is Zomedica stock dropping?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
Why did Zomedica stock go up today?
Shares of Zomedica (ZOM -0.25%) were soaring 14.7% higher as of 11:41 a.m. ET on Monday. The big jump came after the veterinary health company provided a sneak peek at its 2021 fourth-quarter and full-year revenue following the market close on Friday.
Is Zomedica a real company?
About us. Zomedica (NYSE American:ZOM) is a veterinary health company focused on meeting the needs of clinical veterinarians in ways that promote both patient and practice health.
How many outstanding shares does Zomedica have?
979.9MShare StatisticsAvg Vol (3 month) 323.07MShares Outstanding 5979.9MImplied Shares Outstanding 6N/AFloat 8966.83M% Held by Insiders 11.48%7 more rows
Does ZOM stock pay dividends?
ZOM does not currently pay a dividend.
ZOMEDICA STOCK FORECAST 2022, 2023, 2024
Zomedica's stock was trading at $0.3201 at the beginning of the year. Since then, ZOM shares have decreased by 22.8% and is now trading at $0.2470....
Zoom Stock: Buy, Sell, or Hold in 2022? | The Motley Fool
Zomedica saw a increase in short interest in May. As of May 15th, there was short interest totaling 112,640,000 shares, an increase of 23.4% from t...
How has Zomedica's stock price performed in 2022?
Zomedica is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Zomedica .
Are investors shorting Zomedica?
Zomedica Corp. (NYSEAMERICAN:ZOM) announced its quarterly earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per s...
When is Zomedica's next earnings date?
Zomedica updated its FY 2021 earnings guidance on Monday, March, 21st. The company provided earnings per share (EPS) guidance of for the period. Th...
How were Zomedica's earnings last quarter?
Zomedica's management team includes the following people: Mr. Larry C. Heaton II , Pres & CEO (Age 65, Pay $488k) Ms. Ann Marie Cotter CPA , CF...
What guidance has Zomedica issued on next quarter's earnings?
Some companies that are related to Zomedica include Amneal Pharmaceuticals (AMRX) , Amneal Pharmaceuticals (AMRX) , Aclaris Therapeutics (ACRS)...
Who are Zomedica's key executives?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."
Who are some of Zomedica's key competitors?
Zomedica's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.14%), Stat...
What is Zomedica's stock symbol?
Who are Zomedica's major shareholders?
About Zomedica
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs.
Zomedica (NYSEAMERICAN:ZOM) Frequently Asked Questions
Zomedica's stock was trading at $0.2078 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZOM stock has increased by 63.8% and is now trading at $0.3403. View which stocks have been most impacted by COVID-19.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
More About Zomedica Corp
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health.
How much did Zomedica raise?
Like many other WallStreetBets pumped stocks, Zomedica went on a share selling spree. It raised almost $200 million from a bought deal with H.C. Wainwright. The issuance was way above what the company was originally planning.
Is Truforma a good stock to buy?
From a product standpoint, Truforma looks like a good bet. If Zomedica can successfully commercialize Truforma, the stock could be a good buy. However, like all companies in the pre-revenue stage, it's still a high-risk bet. In markets, risk and return tend to go hand in hand. Advertisement.
Will the Zom stock rise or fall?
Will ZOM stock rise or fall? In the short term, ZOM stock might still be susceptible to a fall. However, the stock could be getting near its bottom now. If you are a patient investor and can hold the stock for the long term, it could turn out to be a winner.
Is there a bloodbath in penny stocks?
There has been a bloodbath in all of the penny names , especially those that were pumped by WallStreetBets. While short squeezes that WallStreetBets triggered can impact the short-term price movement, in the medium to long term, stocks tend to trade according to their fundamental value.
Is Zomedica a penny stock?
Zomedica (ZOM) is one of the most popular penny stocks among retailer traders. It was pumped by the Reddit group WallStreetBets, which took the stock to as high as $2.91. However, it's back under $1 now. What’s the long-term forecast for ZOM stock? Will it rise or fall by 2025?
When did Zomedica stock surge?
Zomedica stock surged in Jan. 2021 following a shout-out from Tiger King ’s Carole Baskin. She praised Zomedica’s efforts to help veterinarians care for sick pets, and stated that she was “invested” in learning more about the company.
How much will Zomedica spend in 2025?
Additionally, with pet ownership on the rise, Zomedica has a huge growth opportunity. Global spending on pet care products is on track to grow to $200 billion by 2025 from $131 billion in 2016, and the animal diagnostic market is forecast to grow to $9.5 billion by 2026 from $4.4 billion in 2018. Advertisement.
Is Zomedica a long term investment?
Now with a product on the market and a basis for sustainable recovery, Zomedica can attract long-term investors. The company didn’t generate any revenue in 2020, but that's set to change with Truforma on the market. At its current low price, ZOM stock may also attract bargain hunters. Article continues below advertisement.
What would happen if Zomedica was bought?
If Zomedica was acquired, Wickfield again would have earned $108 million. At this valuation, the preferred stock wouldn’t have presented a massive roadblock to a sale; a company willing to pay $2 billion for Zomedica would have been able to manage the extra payment to Wickfield.
How much did Zomedica raise in 2019?
Desperate, the company in May 2019 entered into a financing agreement with heavily onerous terms. In the process, the company raised $12 million which kept it afloat until the market took notice of ZOM stock toward the end of last year. Then, last month, Zomedica retired those preferred shares.
Did Wickfield liquidate Zomedica?
If Zomedica went under and into a liquidation, Wickfield essentially had claim to all of the company’s assets, given a so-called “liquidation preference,” also $108 million less royalties paid. Simply put, this was a brutal deal for Zomedica, but it was likely the only deal available, and, of course, it worked.
Did Zomedica go bankrupt?
The Form 10-K filed with the U.S. Securities and Exchange Commission contained a “going concern” notification warning investors that the company might not make it through 2019 without filing for bankruptcy.
Is Zomedica running out of cash?
Back in 2019, Zomedica (NASDAQ: ZOM) was in enormous trouble. The company was running out of cash, and with the ZOM stock price below 50 cents, it was also running out of options. Indeed, Zomedica closed 2018 with less than $2 million in cash. It had burned nearly $12 million that year.
Is Zomedica owned by Qorvo?
Zomedica’s technology isn’t owned, but instead licensed from Qorvo ( NASDAQ: QR VO ). Qorvo sold that license for total consideration of about $15 million. There is a narrative around ZOM stock that suggests this is some innovative company with an enormously bright future.
How much did Zomedica raise?
True, Zomedica did manage to raise a total of $217 million during the year which brought its cash to nearly $278 million as of Feb. 26. For a company that reported a loss of almost $17 million, this cash cushion looks positive and healthy. However, if ZOM’s sales increase, its expenditure will also go higher.
Is Zomedica delisted?
So, ZOM’s cash cushion may not be as comfortable as it seems at first glance. Yes, Zomedica was close to being delisted recently, so its ability to launch the commercial sale of Truforma is definitely a feat. However, investors must look at it from a different angle.
Is Zomedica a penny stock?
Recently, Zomedica (NYSEAMERICAN: ZOM) — a veterinary diagnostic company — has become a play on that trend. In fact, although one of the penny stocks, ZOM stock has seen a lot of action in the past few months. Adding to the heat, Zomedica recently announced the first commercial sale of its new product, the Truforma diagnostic platform.
